Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399809 · ClinicalTrials.gov registry record · Phase 2
Fisetin to Reduce Senescence and Mobility Impairment in PAD
A Phase 2 study of Aging and Peripheral Arterial Disease, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06399809: Recruiting Phase 2 study of Aging and Peripheral Arterial Disease, sponsored by Northwestern University.
NCT06399809 is a Phase 2 study of Aging and Peripheral Arterial Disease that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 34 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06399809, a Phase 2 study of Aging and Peripheral Arterial Disease, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.
Primary Outcome
Among older people with PAD, the investigators will determine whether, compared to placebo, fisetin improves six-minute walk distance at 4-month follow-up
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fisetin
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT06399809 shows while recruiting
NCT06399809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06399809 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06399809 about?
NCT06399809 is a clinical study titled "Fisetin to Reduce Senescence and Mobility Impairment in PAD". The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with periphera...
What is the current status of trial NCT06399809?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2024-09-30. Estimated completion is 2027-06.
What conditions does trial NCT06399809 study?
This clinical trial studies the following conditions: Aging, Peripheral Arterial Disease, Peripheral Vascular Diseases, Walking, Difficulty, Claudication.
What interventions are being tested in trial NCT06399809?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT06399809?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399809 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06399809's enrollment target sits among peer trials
34 184th of 262 higher than 77 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Empagliflozin Reversal of Arterial StiffnEss in Aging
RECRUITING · Phase 2
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
Acetate and Age-associated Arterial Dysfunction
RECRUITING · Phase 2
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI